{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:47:26Z","timestamp":1776973646339,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1898,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014935","name":"BioCryst Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1093\/annonc\/mdu231","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T06:59:12Z","timestamp":1403247552000},"page":"1807-1812","source":"Crossref","is-referenced-by-count":39,"title":["Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and S\u00e9zary syndrome)"],"prefix":"10.1016","volume":"25","author":[{"given":"R.","family":"Dummer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.A.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rozati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Eggmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.M.","family":"Illidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Elder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1093\/annonc\/mdu231_bb0010","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1093\/annonc\/mdu231_bb0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminoncol.2012.01.010","article-title":"Recent advances in the management of cutaneous lymphomas","volume":"39","author":"Belloni","year":"2012","journal-title":"Semin Oncol"},{"issue":"3 Pt 1","key":"10.1093\/annonc\/mdu231_bb0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/jid.2011.370","article-title":"Cutaneous lymphomas: molecular pathways leading to new drugs","volume":"132","author":"Dummer","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1093\/annonc\/mdu231_bb0025","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1567-5769(03)00076-6","article-title":"Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor\u2014BCX-1777","volume":"3","author":"Bantia","year":"2003","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1093\/annonc\/mdu231_bb0030","first-page":"45","article-title":"Purine nucleoside phosphorylase deficiency","volume":"3","author":"Markert","year":"1991","journal-title":"Immunodefic Rev"},{"issue":"13","key":"10.1093\/annonc\/mdu231_bb0035","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2005-03-1309","article-title":"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)","volume":"106","author":"Gandhi","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1093\/annonc\/mdu231_bb0040","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1073\/pnas.071050798","article-title":"Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes","volume":"98","author":"Kicska","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1093\/annonc\/mdu231_bb0045","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2217\/fon.10.83","article-title":"Forodesine: review of preclinical and clinical data","volume":"6","author":"Al-Kali","year":"2010","journal-title":"Future Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdu231_bb0050","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and S\u00e9zary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdu231_bb0055","first-page":"122","article-title":"Response to oral forodesine in refractory cutaneous T-Cell lymphoma: interim results of a phase I\/II study","volume":"110","author":"Duvic","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"10.1093\/annonc\/mdu231_bb0060","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1349-7006.2012.02287.x","article-title":"Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T\/natural killer-cell malignancies","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1093\/annonc\/mdu231_bb0065","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/molecules14031183","article-title":"Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases","volume":"14","author":"Robak","year":"2009","journal-title":"Molecules"},{"issue":"8","key":"10.1093\/annonc\/mdu231_bb0070","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2009-02-207654","article-title":"Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM","volume":"114","author":"Alonso","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mdu231_bb0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/157489211793980051","article-title":"Novel systemic drugs for cutaneous T-cell lymphoma","volume":"6","author":"Lech-Maranda","year":"2011","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"6","key":"10.1093\/annonc\/mdu231_bb0080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"29","key":"10.1093\/annonc\/mdu231_bb0085","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu231_bb0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -na\u00efve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1093\/annonc\/mdu231_bb0095","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"A prospective international multicentre phase II trial of intravenous pegylated liposomal doxorubicin (PLD) mono-chemotherapy in patients with advanced Mycosis fungoides stage IIB, IVA and IVB (Final Results from EORTC 21012)","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdu231_bb0100","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1365-4362.1997.00329.x","article-title":"Cutaneous T-cell lymphoma","volume":"36","author":"Dalton","year":"1997","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1093\/annonc\/mdu231_bb0105","first-page":"276","article-title":"Mycosis fungoides and the S\u00e9zary syndrome","volume":"26","author":"Kim","year":"1999","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdu231_bb0110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/13543784.2014.876407","article-title":"Novel therapies for cutaneous T-cell lymphoma: what does the future hold?","volume":"23","author":"Guenova","year":"2014","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419351099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419351099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:42:09Z","timestamp":1624520529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419351099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0923753419351099"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu231","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}